Media About Us


  • 09 June 2016

    Treatment for age related loss of near vision: Raindrop near vision inlay one-year clinical results

    Treatment for age related loss of near vision: Raindrop near vision inlay one-year clinical results

    Jeffrey Whitman, MD Key-Whitman Eye Center, Dallas, TX, USA / Atlas of Science

    Presbyopia is an ocular condition associated with age related loss of near vision. The eye loses the ability to focus well on near objects due to the hardening of the natural lens. It affects billions of people worldwide with the onset occurring around age 45. The most common treatment for presbyopia is the use of reading glasses. Recently, surgical correction of presbyopia has been tested as part of a clinical study by implanting a small device into the cornea, the clear front part of the eye.  The Raindrop Near Vision Inlay is an investigational device that is being evaluated to treat this condition so that dependence upon reading glasses may be reduced in order to see objects up close.

  • 13 May 2016

    Good long-term visual acuities reported in presbyopic patients implanted with Raindrop inlay

    Good long-term visual acuities reported in presbyopic patients implanted with Raindrop inlay

    Healio

    Good long-term visual acuities for distance and near were achieved in presbyopic patients, both emmetropic and hyperopic, implanted with the ReVision Optics Raindrop inlay, according to a study presented by Cornelis Verdoorn, MD, at the American Society of Cataract and Refractive Surgery meeting here.

  • 13 May 2016

    Clearside Biomedical Announces Potential Pricing for IPO

    Chris Lange / 24/7 Wall St.

    Clearside Biomedical has filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). The company expects to price its 4 million shares in the range of $14 to $16 per share, with an overallotment option for an additional 600,000 shares. At the maximum price the entire offering is valued up to $73.6 million. The company intends to list its shares on the Nasdaq Global Market under the symbol CLSD.

  • 18 April 2016

    Marinus Pharmaceuticals Receives Orphan Drug Status for Ganaxolone as Treatment for Status Epilepticus

    Marinus Pharmaceuticals Receives Orphan Drug Status for Ganaxolone as Treatment for Status Epilepticus

    Robin Reyes / SonoranWeeklyReview.com

    Marinus Pharmaceuticals (NASDAQ:MRNS) has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for ganaxolone for the treatment of status epilepticus, according to the agency’s website. Status epilepticus is a dangerous condition in which epileptic seizures follow one another without recovery of consciousness between them. 

  • 05 April 2016

    Breaking the Test Tube Ceiling

    Breaking the Test Tube Ceiling

    Josh Baxt / San Diego Magazine

    At a recent high school night, curious middle schoolers and parents listened intently as schools talked up their programs. The speeches were formulaic, and mercifully brief, but at one point, the rep from a technology-oriented high school targeted a specific audience. “Girls,” she said, “don’t let the tech part scare you.”

  • 16 March 2016

    Multiple STIs could be detected with researchers developing a single 30 minute test

    Multiple STIs could be detected with researchers developing a single 30 minute test

    HealthCanal

    One test that could detect four of the most common sexually transmitted infections in 30 minutes and allow them to be rapidly treated, will be developed by St George’s, University of London and diagnostics company Atlas Genetics.

  • 15 March 2016

    Despite Turbulence, RussiaТs Pharma Market Holds Promise

    Despite Turbulence, RussiaТs Pharma Market Holds Promise

    Kim Ribbink / PharmaVoice.com

    The world’s largest nation, Russia remains an attractive market for most industries. Nevertheless, the country has struggled through a rough economic period, rocked by a drop in the value of the currency and turbulence in the oil market. Geopolitical pressures have raised challenges, including sanctions imposed on the country.

  • 04 March 2016

    Syndax braves a market tempest in second IPO try, scores a $53M raise

    Syndax braves a market tempest in second IPO try, scores a $53M raise

    John Carroll / FierceBiotech

    Syndax ($SNDX) has joined a small group of biotechs that has managed to price an IPO in the face of gale force market headwinds. The biotech had to go well under its projected range, though, and settle for $12.

  • 03 March 2016

    Syndax Cuts Price But Bags $53M in Second IPO Try

    Syndax Cuts Price But Bags $53M in Second IPO Try

    Ben Fidler / Xconomy

    Over the past year, Syndax Pharmaceuticals has altered its strategic course and hired new management to implement it. And it looks like that change was big enough to propel Waltham, MA-based Syndax through the IPO queue on its second attempt since late 2014—albeit not on the terms the company had hoped for.

  • 24 February 2016

    Syndax readies its 2nd IPO attempt during a market tempest

    Syndax readies its 2nd IPO attempt during a market tempest

    John Carroll / FierceBiotech

    Looking to cash in on its eventful past year, Syndax is upping its bet on a turbulent market with an IPO that will seek to garner about $66 million. The last time Syndax made a try at an IPO, it set out for a $60 million windfall. But this time, it's looking to trade on the rep of its new, high-profile CEO--AstraZeneca vet Briggs Morrison--and a string of partnerships with a who's who in immuno-oncology by selling 4.4 million shares at $14 to $16 per share. At most, it could gain up to $70 million, though the odds against a top-of-the-range response are intimidating.